GSK plc (GLAXF)
- Previous Close
19.64 - Open
19.64 - Bid 18.45 x 47300
- Ask 20.00 x 29200
- Day's Range
19.64 - 19.64 - 52 Week Range
16.80 - 23.00 - Volume
400 - Avg. Volume
3,256 - Market Cap (intraday)
81.58B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
13.61 - EPS (TTM)
1.47 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield 0.78 (3.92%)
- Ex-Dividend Date Aug 15, 2024
- 1y Target Est
--
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
www.gsk.com70,212
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GLAXF
View More
Performance Overview: GLAXF
Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLAXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLAXF
View MoreValuation Measures
Market Cap
78.85B
Enterprise Value
97.08B
Trailing P/E
13.56
Forward P/E
8.55
PEG Ratio (5yr expected)
1.26
Price/Sales (ttm)
1.76
Price/Book (mrq)
4.34
Enterprise Value/Revenue
2.36
Enterprise Value/EBITDA
9.19
Financial Highlights
Profitability and Income Statement
Profit Margin
12.83%
Return on Assets (ttm)
9.56%
Return on Equity (ttm)
33.30%
Revenue (ttm)
31.45B
Net Income Avi to Common (ttm)
4.03B
Diluted EPS (ttm)
1.47
Balance Sheet and Cash Flow
Total Cash (mrq)
2.98B
Total Debt/Equity (mrq)
123.04%
Levered Free Cash Flow (ttm)
5.5B
Research Analysis: GLAXF
View MoreCompany Insights: GLAXF
GLAXF does not have Company Insights
Research Reports: GLAXF
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, global oil inventories face future; feeling the internet's backbone; and initiating coverage of Qualys; and Lithium Americas, Bausch & Lomb and Macy's.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.